INKT vs MET · $59.1M cap vs P/E 13, rev $38.23B
Mink Therapeutics Inc (INKT) versus MetLife Inc (MET) — a side-by-side from cached financials, not a winner call.
Mink Therapeutics Inc (INKT) is a biotechnology company listed on US.
MetLife Inc (MET) is a insurance - life company listed on US.
INKT does not have a complete income-statement cache yet.
Latest reported MET revenue for 2026-06-30 was $38.23B. Net income was $1.92B. MET currently screens at market cap $52.16B and trailing P/E 12.7.
INKT currently screens at market cap $59.1M. MET currently screens at market cap $52.16B and trailing P/E 12.7.
Not investment advice. Open the INKT and MET stock pages for the full models.
Not investment advice.